- Home
- TCRX vs PFX Comparison
TCRX vs PFX Comparison
Compare TCRX & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- PFX
- Stock Information
- Founded
- TCRX 2018
- PFX 2010
- Country
- TCRX United States
- PFX United States
- Employees
- TCRX N/A
- PFX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- PFX Finance: Consumer Services
- Sector
- TCRX Health Care
- PFX Finance
- Exchange
- TCRX Nasdaq
- PFX Nasdaq
- Market Cap
- TCRX 90.5M
- PFX 101.2M
- IPO Year
- TCRX 2021
- PFX N/A
- Fundamental
- Price
- TCRX $1.45
- PFX $49.00
- Analyst Decision
- TCRX Strong Buy
- PFX
- Analyst Count
- TCRX 6
- PFX 0
- Target Price
- TCRX $9.50
- PFX N/A
- AVG Volume (30 Days)
- TCRX 774.8K
- PFX 1.8K
- Earning Date
- TCRX 05-06-2025
- PFX 05-06-2025
- Dividend Yield
- TCRX N/A
- PFX 2.92%
- EPS Growth
- TCRX N/A
- PFX N/A
- EPS
- TCRX N/A
- PFX 5.09
- Revenue
- TCRX $4,421,000.00
- PFX $24,036,577.00
- Revenue This Year
- TCRX $68.86
- PFX $10.51
- Revenue Next Year
- TCRX $14.01
- PFX N/A
- P/E Ratio
- TCRX N/A
- PFX $9.63
- Revenue Growth
- TCRX N/A
- PFX 15.02
- 52 Week Low
- TCRX $1.02
- PFX $44.32
- 52 Week High
- TCRX $9.29
- PFX $57.40
- Technical
- Relative Strength Index (RSI)
- TCRX 49.42
- PFX 40.01
- Support Level
- TCRX $1.33
- PFX $48.75
- Resistance Level
- TCRX $1.49
- PFX $51.50
- Average True Range (ATR)
- TCRX 0.11
- PFX 0.78
- MACD
- TCRX 0.02
- PFX -0.00
- Stochastic Oscillator
- TCRX 69.12
- PFX 16.67
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.